» Articles » PMID: 35633420

Five-year Symptomatic Hemorrhage Risk of Untreated Brainstem Cavernous Malformations in a Prospective Cohort

Overview
Journal Neurosurg Rev
Specialty Neurosurgery
Date 2022 May 28
PMID 35633420
Authors
Affiliations
Soon will be listed here.
Abstract

Hemorrhage of brainstem cavernous malformation (CM) would cause various symptoms and severe disability. The study aimed to elaborate on the 5-year actuarial cumulative hazard of symptomatic hemorrhage. Patients diagnosed in our institute between 2009 and 2013 were prospectively registered. All clinical data were obtained, follow-up was performed, and risk factors were evaluated. Four hundred sixty-eight patients (217 female, 46.4%) were included in the study with a median follow-up duration of 79.0 months. A total of 137 prospective hemorrhages occurred in 107 patients (22.9%) during 1854.0 patient-years. Multivariate Cox analysis found age ≥ 55 years (hazard ratio (HR) 2.166, p = 0.002), DVA (HR 1.576, p = 0.026), superficial-seated location (HR 1.530, p = 0.047), and hemorrhage on admission (HR 2.419, p = 0.026) as independent risk factors for hemorrhage. The 5-year cumulative hazard of hemorrhage was 30.8% for the overall cohort, 47.8% for 60 patients with age ≥ 55 years, 43.7% for 146 patients with DVA, 37.9% for 272 patients with superficial-seated lesions, and 37.2% for 341 patients with hemorrhage on admission. As a stratified analysis, within subcohort of 341 patients with a hemorrhagic presentation, age ≥ 55 years (HR 3.005, p < 0.001), DVA (HR 1.801, p = 0.010), and superficial-seated location (HR 2.276, p = 0.001) remained independently significant. The 5-year cumulative hazard of hemorrhage was 52.0% for 119 patients with both DVA and hemorrhagic presentation. The 5-year cumulative hemorrhagic risk was 30.8% and was higher in subgroups if harboring risk factors that helped to predict potential hemorrhagic candidates and were useful for treatment decision-making.Clinical Trial Registration-URL: http://www.chictr.org.cn Unique identifier: ChiCTR-POC-17011575.

Citing Articles

Identifying potential (re)hemorrhage among sporadic cerebral cavernous malformations using machine learning.

Li X, Jones P, Zhao M Sci Rep. 2024; 14(1):11022.

PMID: 38745042 PMC: 11094099. DOI: 10.1038/s41598-024-61851-4.


The Brainstem Cavernoma Case Series: A Formula for Surgery and Surgical Technique.

Tatagiba M, Lepski G, Kullmann M, Krischek B, Danz S, Bornemann A Medicina (Kaunas). 2023; 59(9).

PMID: 37763720 PMC: 10537097. DOI: 10.3390/medicina59091601.


Are there differences in clinical presentation, radiologic findings, and outcomes in female patients with cavernous malformation?.

Flemming K, Lanzino G Acta Neurochir (Wien). 2023; 165(7):1855-1861.

PMID: 37306819 DOI: 10.1007/s00701-023-05652-0.

References
1.
Akers A, Salman R, Awad I, Dahlem K, Flemming K, Hart B . Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery. 2017; 80(5):665-680. PMC: 5808153. DOI: 10.1093/neuros/nyx091. View

2.
Salman R, Berg M, Morrison L, Awad I . Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board. Stroke. 2008; 39(12):3222-30. DOI: 10.1161/STROKEAHA.108.515544. View

3.
Salman R, Hall J, Horne M, Moultrie F, Josephson C, Bhattacharya J . Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol. 2012; 11(3):217-24. PMC: 3282211. DOI: 10.1016/S1474-4422(12)70004-2. View

4.
Salman R, Kitchen N, Thomson J, Ganesan V, Mallucci C, Radatz M . Top ten research priorities for brain and spine cavernous malformations. Lancet Neurol. 2016; 15(4):354-5. DOI: 10.1016/S1474-4422(16)00039-9. View

5.
Chen B, Herten A, Saban D, Rauscher S, Radbruch A, Schmidt B . Hemorrhage from cerebral cavernous malformations: The role of associated developmental venous anomalies. Neurology. 2020; 95(1):e89-e96. DOI: 10.1212/WNL.0000000000009730. View